PATENT COOPERATION TREATY

PCT

INTERNATIONAL SEARCH REPORT

(PCT Article 18 and Rules 43 and 44)

Applicant's or agent's file reference	FOR FURTHER	see Form PCT/ISA/220
P03/126-do/rg	ACTION a	as well as, where applicable, item 5 below.
International application No.	International filing date (day/month/yea	ar) (Earliest) Priority Date (day/month/year)
PCT/EP2004/006337	11/06/2004	11/07/2003
Applicant		
MERCK PATENT GMBH		
This International Search Report has bee according to Article 18. A copy is being tra		g Authority and is transmitted to the applicant
This International Search Report consists	of a total of 7 sheets	
	a copy of each prior art document cited i	
,		
	international search was carried out on t less otherwise indicated under this item.	he basis of the international application in the
The international this Authority (Ru		translation of the international application furnished to
b. With regard to any nucleo	otide and/or amino acid sequence disc	closed in the international application, see Box No. I.
2. Certain claims were fou	nd unsearchable (See Box II).	· •
3 Unity of invention is lac	king (see Box III).	• • • •
4. With regard to the title,		
the text is approved as su	ibmitted by the applicant.	
X the text has been establis	shed by this Authority to read as follows:	
BENZIMIDAZOLE CARBOXAN	TIDES AS RAF KINASE INHIE	BITORS
5. With regard to the abstract,		
the text is approved as su	bmitted by the applicant.	
X the text has been establis	hed, according to Rule 38.2(b), by this A	uthority as it appears in Box No. IV. The applicant
may, within one month fro	om the date of mailing of this international	I search report, submit comments to this Authority.
6. With regards to the drawings,		•
	published with the abstract is Figure No	
as suggested by		
	s Authority, because the applicant failed	to suggest a figure.
	s Authority, because this figure better ch	
b. none of the figures is to b	e published with the abstract.	

Box No. IV Text of the abstract (Continuation of item 5 of the first sheet)

The present invention relates to benzimidazole carboxamides of formula, I, the use of the compounds of formula I as inhibitors of as inhibitors of one or more kinases, the use of the compounds of formula I for the manufacture of a pharmaceutical composition and a method of treatment, comprising administering said pharmaceutical composition to a patient.

Accordingly, the compound of Formula I

or a pharmaceutically acceptable salt thereof is administered for the treatment of diseases mediated by one or more kinase pathways, preferably by the raf kinase pathway, especially cancers.

$$(R^8)_p$$
 N
 N
 N
 R^6
 R^7
 $(R^{10})_r$
 $(R^9)_q$

International Application No PCT/EP2004/006337

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 A61K31/4184 C07D401/12 C07D403/12 A61K31/4439 A61K31/506
A61P35/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 CO7D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, BEILSTEIN Data, PAJ, CHEM ABS Data, WPI Data

C. DOCUM	ENTS CONSIDERED TO BE RELEVANT	
Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to daim No.
Υ	WO 98/22103 A (HEDGE PHILIP JOHN ; ZENECA LTD (GB); BOYLE FRANCIS THOMAS (GB))	1-30
X	28 May 1998 (1998-05-28) claims 7,13; example 3	31
Υ	WO 00/18738 A (BROWN GEORGE ROBERT; ZENECA LTD (GB); BROWN DEARG SUTHERLAND (GB)) 6 April 2000 (2000-04-06)	1-30
X	page 54, line 18 - page 55, line 31; claims 1,5,11 	31
	-/	
X Furti	her documents are listed in the continuation of box C. X Patent family members are listed	in annex.

X Further documents are listed in the continuation of box C.	Patent family members are listed in annex.
 Special categories of cited documents: "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed 	 'T' later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention 'X' document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone 'Y' document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. '&' document member of the same patent family
Date of the actual completion of the international search 31 August 2004	Date of mailing of the international search report 13/09/2004
Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL – 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,	Authorized officer
Fax: (+31-70) 340-3016	Seymour, L

2

International Application No PCT/EP2004/006337

0.40	NAME OF THE PROPERTY OF THE PR	101/21/2004/00033/
C.(Continue	ation) DOCUMENTS CONSIDERED TO BE RELEVANT Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	DATABASE WPI Section Ch, Week 199838 Derwent Publications Ltd., London, GB; Class B02, AN 1998-440271 XP002294310 -& JP 10 182459 A (OTSUKA PHARM CO LTD) 7 July 1998 (1998-07-07) abstract page 12, scheme; examples	1,2,6-31
X	EP 1 101 759 A (NIPPON SODA CO) 23 May 2001 (2001-05-23) page 26, line 1 - line 15; claims 1,4,8-11; tables 2-1 page 68, compound 4-47	1,2,6-31
X	SHARMA P ET AL.: "Synthesis of new 2-(substituted benzothiazolylcarbamoyl) benzimidazoles as potential CNS depressants" INDIAN JOURNAL OF CHEMISTRY, SECTION B: ORGANIC, INCL. MEDICINAL., vol. 38, no. 11, 1999, pages 1289-1294, XP009035803 INPUBLICATIONS & INFORMATIONS DIRECTORATE, NEW DELHI. the whole document	1,2,6-28
X	US 3 661 925 A (MCCAULLY RONALD J ET AL) 9 May 1972 (1972-05-09) column 1, line 30 - line 47; example 3 column 2, line 9 - line 11	1,2,6-11
X	EP 0 284 828 A (BASF AG) 5 October 1988 (1988-10-05) claims 5,7; examples 31,33,34,49,50,75,82,83,89 page 7, line 5 - line 10	1,2,31
X	FR 1 517 719 A (INST FRANCAIS DU PETROL) 22 March 1968 (1968-03-22) formula II page 2, right-hand column	1,2
X	DATABASE CAPLUS CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 1984, XP002294308 Database accession no. 101:23395 (DN) RN 90681-10-0 & PETYUNIN P A ET AL.: DEPOSITED DOC., SPSTL 920 KHP-D82, 1982,	1,2

International Application No PCT/EP2004/006337

212	ALL DOOUMENTS CONCIDENTS TO BE DELEVANT	14/00633/
Category °	ation) DOCUMENTS CONSIDERED TO BE RELEVANT Citation of document, with indication, where appropriate, of the relevant passages	 Relevant to claim No.
X	DATABASE CAPLUS CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 5 June 2003 (2003-06-05), XP002294309 Database accession no. 139:292169 (DN) RN 608143-72-2, 608143-73-3, 608143-74-4, 608143-63-1, 608143-64-2, 608143-65-3 & CIUGUREANU C: REVISTA DE CHIMIE, vol. 54, no. 3, 2003, pages 236-240, BUCHAREST, ROMANIA	1,2
P,X	VARNAVAS A ET AL: "Anthranilic acid based CCK1 antagonists: the 2-indole moiety may represent a ''needle'' according to the recent homonymous concept" EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, EDITIONS SCIENTIFIQUE ELSEVIER, PARIS, FR, vol. 39, no. 1, January 2004 (2004-01), pages 85-97, XP004492422 ISSN: 0223-5234 figure 2; table 1	1,2,6-31

International application No. PCT/EP2004/006337

INTERNATIONAL SEARCH REPORT

Box II	Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)
This Inte	rnational Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:
1. χ	Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely: Although claims 12,13,15-28 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2.	Claims Nos.: because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3.	Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).
Box III	Observations where unity of invention is lacking (Continuation of item 3 of first sheet)
This Inte	rnational Searching Authority found multiple inventions in this international application, as follows:
1.	As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2.	As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3.	As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4.	No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:
Remark	on Protest The additional search fees were accompanied by the applicant's protest. No protest accompanied the payment of additional search fees.

Information on patent family members

International Application No
PCT/EP2004/006337

						2004/00033/
	atent document in search report		Publication date		Patent family member(s)	Publication date
WO	9822103	Α	28-05-1998	AU	4956297 A	10-06-1998
				CA	2267782 A1	28-05-1998
				EP	0941084 A1	15-09-1999
				WO	9822103 A1	28-05-1998
				JP	2001504478 T	03-04-2001
				NO	992336 A	14-05-1999
				ZA	9710314 A	18-05-1998
WO	0018738	Α	06-04-2000	AT	254105 T	15-11-2003
				AU	761361 B2	05-06-2003
				AU	6103499 A	17-04-2000
				BR	9913947 A	12-06-2001
				CA	2340454 A1	06-04-2000
		•		CN DE	1319092 T	24-10-2001 18-12-2003
				DK	69912823 D1 1115707 T3	01-03-2004
				EP	1115707 13 1115707 A1	18-07-2001
				ES	2211172 T3	01-07-2004
				MO	0018738 A1	06-04-2000
				HK	1038556 A1	30-04-2004
				HÙ	0104060 A2	28-03-2002
				ID	28267 A	10-05-2001
				JP	2002525358 T	13-08-2002
				NO	20011492 A	23-05-2001
	•			NZ	509836 A	30-06-2003
				PL	346854 A1	11-03-2002
				PT	1115707 T	30-04-2004
				RU	2219171 C2	20-12-2003
				SK	4212001 A3	06-08-2001
				TR	200100840 T2	22-10-2001
				US Za	6455520 B1 200102185 A	24-09-2002 18-06-2002
JP	10182459 	A 	07-07-1998 	NONE		
ΕP	1101759	Α	23-05-2001	AU	753360 B2	17-10-2002
				AU	4929799 A	21-02-2000
				CA	2339123 A1	10-02-2000
				EP	1101759 A1	23-05-2001
				US	6342516 B1	29-01-2002
				CN	1131217 B	17-12-2003
				WO	0006550 A1	10-02-2000
				JP	2000290280 A	17-10-2000
				JP	2000281656 A	10-10-2000
				JP	2000281658 A	10-10-2000
US	3661925	Α	09-05-1972	US	3740413 A	19-06-1973
EP 0284828	0284828	Α	05-10-1988	DE	3708292 A1	29-09-1988
				DE	3865478 D1	21-11-1991
				EP	0284828 A1	05-10-1988
				ES	2026586 T3	01-05-1992
					2663975 B2	15-10-1997
				JP		00_11_1000
				JP	63270669 A	08-11-1988
					63270669 A 4820757 A	08-11-1988 11-04-1989